Ownership
Private
Employees
~1200
Therapeutic Areas
HematologyImmunologyCardiovascularInfectious Diseases
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
BiologicProtein (plasma-derived)Recombinant protein (for some products)Enzyme replacement therapy (for antithrombin III concentrate)

Japan Blood Products Organization General Information

Japan Blood Products Organization manufactures and supplies a range of commercialized plasma-derived medicinal products including human normal immunoglobulin, anti-HBs immunoglobulin, human serum albumin, freeze-dried concentrated human antithrombin III, freeze-dried coagulation factor VIII concentrate, and haptoglobin. The company emphasizes safety and security in its production processes. It has also engaged in humanitarian aid by donating clotting factors to global programs supporting patients with bleeding disorders.

Contact Information

Primary Industry
Biotech
Corporate Office
Tokyo,
Japan

Drug Pipeline

No pipeline data available

For full access to Japan Blood Products Organization's pipeline data

Book a demo

Key Partnerships

Collaboration/donation partnership with World Federation of Hemophilia Humanitarian Aid Program, historical links to Mitsubishi Tanabe Pharma Group/Benesis Corporation/Japanese Red Cross Society

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Japan Blood Products Organization Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Japan Blood Products Organization's complete valuation and funding history, request access »

Japan Blood Products Organization Financial Metrics